Total Payments
$105,772
2024 Payments
$2,766
Companies
15
Transactions
58
Medicare Patients
1,016
Medicare Billing
$198,334
Payment Breakdown by Category
Consulting$65,227 (61.7%)
Research$25,355 (24.0%)
Other$9,000 (8.5%)
Travel$5,009 (4.7%)
Food & Beverage$1,064 (1.0%)
Education$116.61 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $65,227 | 20 | 61.7% |
| Unspecified | $25,355 | 7 | 24.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,000 | 2 | 8.5% |
| Travel and Lodging | $5,009 | 11 | 4.7% |
| Food and Beverage | $1,064 | 15 | 1.0% |
| Education | $116.61 | 3 | 0.1% |
Payments by Type
General
$80,417
51 transactions
Research
$25,355
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $31,195 | 13 | $0 (2021) |
| MacroGenics, Inc. | $23,601 | 3 | $0 (2021) |
| AstraZeneca UK Limited | $14,230 | 3 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $8,383 | 9 | $0 (2020) |
| SANOFI US SERVICES INC. | $5,992 | 1 | $0 (2023) |
| Boehringer Ingelheim International GmbH | $4,986 | 5 | $0 (2018) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $4,648 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $3,355 | 5 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $2,939 | 5 | $0 (2017) |
| Seagen Inc. | $2,070 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,766 | 3 | AstraZeneca UK Limited ($2,055) |
| 2023 | $5,992 | 1 | SANOFI US SERVICES INC. ($5,992) |
| 2021 | $52,080 | 9 | AstraZeneca Pharmaceuticals LP ($24,500) |
| 2020 | $2,514 | 5 | F. Hoffmann-La Roche AG ($1,161) |
| 2019 | $14,549 | 7 | AstraZeneca UK Limited ($12,175) |
| 2018 | $9,158 | 9 | Boehringer Ingelheim International GmbH ($4,986) |
| 2017 | $18,712 | 24 | Merck Sharp & Dohme Corporation ($8,269) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 09/17/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $367.87 | General |
| 07/30/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $343.00 | General |
| 02/21/2023 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $5,992.00 | General |
| 12/27/2021 | Seagen Inc. | — | Consulting Fee | Cash or cash equivalent | $588.80 | General |
| 12/09/2021 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2021 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 04/05/2021 | MacroGenics, Inc. | — | — | Cash or cash equivalent | $11,092.48 | Research |
| Study: A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | ||||||
| 04/05/2021 | MacroGenics, Inc. | — | — | Cash or cash equivalent | $7,788.34 | Research |
| Study: A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | ||||||
| 04/05/2021 | MacroGenics, Inc. | — | — | Cash or cash equivalent | $4,720.20 | Research |
| Study: A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | ||||||
| 02/18/2021 | Seagen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 01/22/2021 | Novocure Inc. | NovoTTF-100L (Device) | Consulting Fee | Cash or cash equivalent | $960.00 | General |
| Category: Oncology | ||||||
| 01/07/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $24,500.00 | General |
| Category: Oncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $752.78 | Research |
| Study: A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA MORPHEUS-PANCREATIC CANCER • Category: BioOncology | ||||||
| 08/21/2020 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,137.50 | General |
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $408.34 | Research |
| Study: A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA MORPHEUS-PANCREATIC CANCER • Category: BioOncology | ||||||
| 01/27/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $114.12 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2020 | Seagen Inc. | — | — | In-kind items and services | $101.67 | Research |
| Study: A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | ||||||
| 08/11/2019 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| 07/15/2019 | AstraZeneca UK Limited | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,925.00 | General |
| Category: Oncology | ||||||
| 06/28/2019 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $9,250.00 | General |
| 06/02/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $115.15 | General |
| Category: Oncology | ||||||
| 06/01/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 05/31/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 05/30/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $49.06 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | MacroGenics, Inc. | $23,601 | 3 |
| A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA MORPHEUS-PANCREATIC CANCER | F. Hoffmann-La Roche AG | $1,161 | 2 |
| A PHASE 1A-1B STUDY OF CXCR4 PEPTIDE ANTAGONIST -LY2510924- ADMINISTERED IN COMBINATION WITH THE ANTI-PD-L1 ANTIBODY, DURVALUMAB -MEDI4736- IN ADVANCED REFRACTORY SOLID TUMORS | Eli Lilly and Company | $491.10 | 1 |
| A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | Seagen Inc. | $101.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 192 | 508 | $211,037 | $44,326 |
| 2022 | 7 | 253 | 542 | $220,531 | $48,385 |
| 2021 | 6 | 241 | 541 | $205,581 | $49,740 |
| 2020 | 10 | 330 | 596 | $217,124 | $55,882 |
Total Patients
1,016
Total Services
2,187
Medicare Billing
$198,334
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 70 | 241 | $85,485 | $19,181 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 51 | 129 | $81,831 | $15,143 | 18.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 57 | $23,622 | $5,668 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 46 | 69 | $16,663 | $3,527 | 21.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 12 | $3,436 | $807.60 | 23.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 73 | 229 | $77,148 | $17,951 | 23.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 53 | 110 | $65,236 | $13,462 | 20.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 61 | $24,354 | $5,260 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 51 | 85 | $19,632 | $4,608 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $20,065 | $4,029 | 20.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $10,358 | $2,173 | 21.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 16 | 17 | $3,738 | $900.78 | 24.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 291 | $95,485 | $24,433 | 25.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 40 | 100 | $56,038 | $12,260 | 21.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 38 | 38 | $27,370 | $6,003 | 21.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 44 | 62 | $13,842 | $3,587 | 25.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 18 | 24 | $7,332 | $2,093 | 28.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 18 | 26 | $5,514 | $1,365 | 24.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 91 | 205 | $64,962 | $13,882 | 21.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 18 | 84 | $13,944 | $13,336 | 95.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 65 | 109 | $57,293 | $10,620 | 18.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 39 | 39 | $27,276 | $5,843 | 21.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 18 | 44 | $16,616 | $4,006 | 24.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 13 | $9,523 | $2,301 | 24.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 29 | 31 | $9,165 | $2,142 | 23.4% |
About Hedy Kindler
Hedy Kindler is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851453302.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Hedy Kindler has received a total of $105,772 in payments from pharmaceutical and medical device companies, with $2,766 received in 2024. These payments were reported across 58 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($65,227).
As a Medicare-enrolled provider, Kindler has provided services to 1,016 Medicare beneficiaries, totaling 2,187 services with total Medicare billing of $198,334. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 12/14/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1851453302
Products in Payments
- LYNPARZA (Drug) $31,083
- Onivyde (Drug) $2,939
- OPDIVO (Biological) $2,218
- Tecentriq (Biological) $1,161
- QINLOCK (Drug) $1,050
- NovoTTF-100L (Device) $960.00
- IMFINZI (Drug) $537.00
- KEYTRUDA (Biological) $114.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678